Methods and Compositions for Treating Osteoarthritis
AssigneesGenascence Corporation, Mayo Foundation for Medical Education and Research
InventorsThomas W. Chalberg, Christopher Howard Evans
Life of this patent
Estimating the term…
Abstract
Methods for treating a human suffering from osteoarthritis are provided. Aspects of the methods include intra-articularly administering to the human a dosage comprising a nucleic acid coding sequence for a human interleukin-1 receptor antagonist (IL-1Ra) to treat the human suffering from osteoarthritis. Also provided are compositions for use in practicing the methods.
Claims15
A method for treating a human suffering from osteoarthritis, the method comprising:
- intra-articularly administering a dosage comprising a nucleic acid coding sequence for a human interleukin-1 receptor antagonist (IL-1Ra) to the human to treat the human suffering from osteoarthritis.
The method according to any of the preceding claims, wherein the coding sequence is present in a vector.
The method according to any of the preceding claims, wherein the coding sequence is operatively linked to a promoter, preferably a non-human promoter, preferably a viral promoter, preferably a cytomegalovirus immediate early promoter.
The method according to any of the preceding claims, wherein the dosage has a volume ranging from 0.25 to 25 ml.
The method according to any of the preceding claims, wherein the human is an adult.
The method according to any of the preceding claims, wherein the osteoarthritis is selected from the group consisting osteoarthritis of the hand, knee, hip, shoulder, ankle, elbow, temporomandibular joint, and spine, and combinations thereof.
A human safe pharmaceutical unit dose comprising an AAV vector comprising a coding sequence for a human IL-1Ra at and an aqueous delivery vehicle.
A kit comprising:
- a pre-unit dose comprising an AAV vector comprising a coding sequence for a human IL-1Ra;
- and
- a diluent;
- wherein combination of the diluent with the pre-unit dose produces a safe pharmaceutical unit dose comprising an AAV vector comprising a coding sequence for a human IL-1Ra at and an aqueous delivery vehicle.
Dependencies are inferred from the claim text.